News
Trailing its RSV vaccine rivals, Bavarian Nordic cuts China ...
Bavarian Nordic has licensed rights to its respiratory syncytial virus (RSV) vaccine in China and certain other Asian markets to Shanghai's Nuance Pharma in a $225 million deal.
